Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many kinds of malignancies including several lymphomas such as Hodgkin's lymphoma, Burkitt's lymphoma and NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the market for clinical use.
Zhang, Xiao; Zhao, Bingchun; Ding, Mingmei; Song, Shuo; Kang, Yinfeng; Yu, Yang; Xu, Miao; Xiang, Tong; Gao, Ling; Feng, Qisheng; Zhao, Qinjian; Zeng, Mu-Sheng; Krummenacher, Claude; and Zeng, Yi-Xin, "A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection." (2020). Faculty Scholarship for the College of Science & Mathematics. 189.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Zhang X, Zhao B, Ding M, Song S, Kang Y, Yu Y, Xu M, Xiang T, Gao L, Feng Q, Zhao Q, Zeng MS, Krummenacher C, & Zeng YX. (2020). A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics 2020; 10(13):5704-5718. doi:10.7150/thno.42494.